Olanzapine is an atypical second generation antipsychotic drug that is used frequently for the treatment of schizophrenia. Cases of olanzapine-related liver toxicity, as well as clozapine crossed toxicity, have been reported (1, 2) .
A case of a patient who developed olanzapine-related liver toxicity is presented.
Case report
This is a 47-year-old patient who was admitted on June 2010 for an acute cholestatic hepatitis of a potential alcoholic origin. The patient had a history of paranoid schizophrenia treated with olanzapine 10 mg/day for the last 11 months. Although the clinical picture evolved satisfactory initially, with the gradual normalization of the liver function tests (bilirubin and coagulation tests), cytolysis was increasingly evident. A complete etiological panel (viruses, antibodies, drugs, etc.) was negative. Since there are cases of olanzapine-related liver toxicity reported in the literature, the drug has been discontinued and switched to haloperidol, with a clear improvement of cytolysis until its complete return to normal.
Discussion
There is a well-known causal relationship between atypical antipsychotic drugs and liver toxicity (1, 3) . Asymptomatic elevation of transaminases is described in the olanzapine label as a common reaction (1-10%), and drug discontinuation is advised in case of hepatitis.
The above mentioned case represents an example of acute hepatitis in a patient with a background liver condition (alcoholic acute hepatitis). When the CIOMS (Council For International Organizations of Medical Sciences) (4) Scale is used, a score of 6 is obtained (probable diagnosis). 
